Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;6(2):91-8.
doi: 10.3978/j.issn.2072-1439.2013.11.16.

Expression and association of CD44v6 with prognosis in T2-3N0M0 esophageal squamous cell carcinoma

Affiliations

Expression and association of CD44v6 with prognosis in T2-3N0M0 esophageal squamous cell carcinoma

Han Yang et al. J Thorac Dis. 2014 Feb.

Abstract

Aim: To investigate the expression of CD44v6 in stage T2-3N0M0 esophageal squamous cell carcinoma (ESCC) and its prognostic significance.

Methods: The expression of CD44v6 in a series of 227 ESCC specimens was evaluated by immunohistochemistry (IHC). A reproducible semiquantitative method which took both staining percentage and intensity into account was applied for IHC scoring, and receiver operating characteristic (ROC) curve analysis was utilized to select the cut-off score for high or low IHC reactivity. Then, the correlations of CD44v6 expression with clinicopathological features of patients and its prognostic relevance were determined.

Results: In the present study, the proportion of low CD44v6 expression was found significantly lower in Grade 3 of ESCC, than that of Grade 1 and Grade 2 of ESCC. There are no significant correlations between CD44v6 expression and other clinicopathological parameters including gender, age, tumor size, tumor location, depth of invasion and pathological stage. The Kaplan-Meier survival curves showed that up-regulated expression of CD44v6 indicated a poorer post-operative survival for ESCC patients of stage T2-3N0M0 (P=0.009), especially for those with T2 lesions (P=0.044) or with stage IIB diseases (P=0.005). Multivariate analysis also confirmed that CD44v6 expression [relative risk, 1.639; 95% confidence interval (CI): 1.142-2.354, P=0.007] and depth of invasion (relative risk, 1.487; 95% CI: 1.063-2.080, P=0.020) were independent prognostic factors.

Conclusions: Elevated CD44v6 expression may be an adverse prognostic indicator for patients with stage T2-3N0M0 ESCC, especially for those with T2 lesions or stage IIB diseases.

Keywords: CD44v6; Esophageal squamous cell carcinoma (ESCC); immunohistochemistry (IHC); prognosis; receiver operating characteristic curve.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of CD44v6 in esophageal squamous cell carcinoma (ESCC) tissue (Envision, ×400). (A) Immunohistochemical staining of CD44v6 in cytoplasm and membrane (IHC score: 15); (B) Immunohistochemical staining of CD44v6 in cytoplasm (IHC score: 3). IHC, immunohistochemistry.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curve analysis for CD44v6 and the selection of cut-off score.
Figure 3
Figure 3
Kaplan-Meier survival function for patients with T2-3N0M0 esophageal squamous cell carcinoma (ESCC) according to CD44v6 expression.
Figure 4
Figure 4
Kaplan-Meier survival curves for patients with esophageal squamous cell carcinoma (ESCC) stratified for depth of invasion according to CD44v6 expression. (A) Correlation between CD44v6 expression and post-operative survival of patients with T2 lesions; (B) Correlation between CD44v6 expression and post-operative survival of patients with T3 lesions.
Figure 5
Figure 5
Kaplan-Meier survival curves for patients with esophageal squamous cell carcinoma (ESCC) stratified for pathological stage according to CD44v6 expression. (A) Correlation between CD44v6 expression and post-operative survival of patients with IIA diseases; (B) Correlation between CD44v6 expression and post-operative survival of patients with IIB diseases.

References

    1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300 - PubMed
    1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917 - PubMed
    1. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41 - PubMed
    1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37Suppl 8:S4-66 - PubMed
    1. Ekman S, Dreilich M, Lennartsson J, et al. Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther 2008;8:1433-48 - PubMed